Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged corticosteroid therapy in scheduled intermediate/high-risk cardiac surgery
2024-517699-39-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF), postoperative respiratory complications (PRC) and Vasoplegia comparing Hydrocortisone + fludrocortisone with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Planned start Aug 2026; status: authorised.
02
Drugs
hydrocortisonefludrocortisone
03
Conditions
acute kidney failure (AKF)postoperative respiratory complications (PRC)Vasoplegia
Beyond the preview
Go deeper on 2024-517699-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517699-39-00.